Risks for diabetes complications, mortality lower with non-vitamin K antagonist oral anticoagulants versus warfarin
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
Guideline addresses management of anticoagulants, antiplatelets during acute gastrointestinal bleeding and in the elective endoscopy setting
Disparities seen among VA patients both for initiating any anticoagulant therapy and for initiating direct-acting oral anticoagulant use
Evidence currently inadequate for assessing the balance of benefits and harms of screening for atrial fibrillation in asymptomatic adults